Skip to main content
13 Jan 2021
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
Read More
9 Jan 2021
18 Dec 2020
4 Dec 2020
20 Nov 2020
17 Nov 2020
UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
Read More
12 Nov 2020
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
Read More
10 Nov 2020
6 Nov 2020
UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020
Read More
31 Oct 2020
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients
Read More
Subscribe to
